28,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
How experienced psychiatrists view the capacity of patients with Alzheimer disease for consenting to research and for appointing a proxy may be related to the patients' conceptualization and memory functioning. 1 key finding →
Participants: 77 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Twenty-one studies based on 18 samples were identified. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Study-specific algorithms yielded comparable dementia prevalence estimates: 10.8 % in NHATS and 11.1 % in HRS-HCAP. 5 key findings →
Participants: 5,696 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This paper reports on a Conference organized by the Washington University School of Medicine's (WUSM) Knight Alzheimer Disease Research Center (Knight ADRC), entitled "Enhancing Participation by Minoritized Groups in Alzheimer Disease and Related Dementia (ADRD) Research." 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Meeting the care needs of people with dementia is a major public health and societal challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The cognitive assessment protocol of the Alzheimer's Disease Cooperative Study (ADCS) was designed to evaluate the reliability and validity of cognitive assessment measures that might be valuable additions to the Alzheimer's Disease Assessment Scale (ADAS) or other concise batteries used in antidementia drug trials.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Pure vascular parkinsonism without evidence of nigral Lewy body pathology may occur as a distinct clinicopathological entity, but a much more frequent occurrence is the comorbid presence of age-associated white matter lesions (WMLs) in idiopathic Parkinson disease (PD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Women living in areas with higher walkability showed slower rates of decline in immediate (estimate=0.019, SE=0.009) and delayed recall (estimate=0.018, SE=0.008) (Figure 1). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Ten‐year Black‐White disparities in prison population are associated with cognitive decline among people racialized as Black starting one year later. 5 key findings →
Participants: 2,300 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among most Latinos in northern Manhattan who learned they had an APOE ε4/ε4 genotype, disclosure did not provoke elevated levels of distress. 3 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Half of GUIDE-eligible PwD received care from multiple caregivers and high strain was common even among caregivers considered "low-complexity" under GUIDE. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
3 network types were identified: "Siloed"-small networks, limited task sharing (29.8% of networks); "Small but Mighty"-small networks, high task sharing (23.0% of networks); and "Complex"-large networks, diverse membership, members who share and specialize in task assistance (47.2%). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
People with dementia have complex medical, functional, and social needs and experience highly variable care quality and outcomes across the U.S. health care system. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Black caregivers reported shorter sleep duration but lower daily pain than White caregivers. 5 key findings →
Participants: 210 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Controlling for demographic/health variables, individuals with aMCI, though not naMCI, showed a higher likelihood of hypertension, diabetes, and hyperlipidemia compared to cognitively normal counterparts, though no differences between aMCI/naMCI. 5 key findings →
Participants: 8,737 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The National Dementia Workforce Study was designed to improve our understanding of the individuals and systems who care for people with dementia, but designing and implementing such a study is challenging due to the large number of patient care organizations, clinical and direct care roles, and locations in which care is provided. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants racialized as Black who lived in places with higher levels of area‐level structural socioeconomic racism experienced lower levels of cognition at baseline and at varying time points in the six‐year period—compared to those in places with lower structural socioeconomic racism. 2 key findings →
Participants: 1,172 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
To balance high-quality measurement of cognitive domains and maintain the ability to perform meaningful cross-national comparisons, each HCAP should include a common set of at least three to four continuously distributed test items per domain that can link domains across studies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We present the pharmacological properties of EKZ-438, which demonstrate high selectivity for HDAC6 (>8500-fold selectivity for HDAC6 versus all other HDAC6 paralogues), low nanomolar potency (12 nM) for HDAC6, and importantly, CNS-penetrance (unbound brain-to-plasma partition coefficient [Kp,uu,brain] ≥ 0.55) and high oral bioavailability (fraction of dose absorbed [F%] = 70). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Genetic variants increase the risk of neurocognitive disorders in later life, including vascular dementia (VaD) and Alzheimer’s disease (AD), but the precise relationships between genetic risk factors and underlying disease etiologies are not well understood. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Non-White race and adverse social and socioeconomic factors-lower education, unemployment, unmarried status, and greater neighborhood disadvantage-were each associated with poorer cognitive performance (p < 0.05). 4 key findings →
Participants: 274 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 563 articles retrieved, 12 met eligibility criteria. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We show that TDP-43 activates GSK3 and promotes caspase-dependent cleavage of TDP-43, generating C-terminal fragments. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Greater perceived control at study baseline was associated with reduced hazard of ADRD. 3 key findings →
Participants: 2,021 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma biomarkers demonstrate promise for improving diagnostic accuracy in diverse research cohorts. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,980 records, built mostly from automated pulls of Europe PMC (62.8% of the library) and OpenAlex (17.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,036 records (3.6% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →